A four-legged precedent for generic user fees
Executive Summary
Discussions between FDA and the Generic Pharmaceutical Association about the creation of a user fee program are on hold, but some generic drug companies are moving forward with another such program - this one for animal products. Led by Ivax's animal health division, the Generic Animal Drug Association has worked out a plan with the administration to add a generic component to the renewal of the animal drug user fee program now working its way through Congress. Whether the program will serve as a guide dog or a canary in the coal mine for the human generic industry remains to be seen
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.